SCHEMBL17409762

SCHEMBL17409762

FC(F)(F)c1cc(Cl)cc(N=S)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 1/20 0.38
AHR P35869 1/20 0.36
ITGB3 P05106 1/20 0.35
ITGAV P06756 1/20 0.35
PLAU P00749 1/20 0.35
NOTUM Q6P988 1/20 0.35
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
ALDH1A1 P00352 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
SLC13A3 Q8WWT9 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13292142 0.84 ITGB3 (0.45) RAPGEF4ITGB3ITGAVPLAUALDH1A1
SCHEMBL14648361 0.79 NOTUM (0.38) RAPGEF4AHRITGB3ITGAVNOTUM
SCHEMBL16013206 0.79 RAPGEF4 (0.35) RAPGEF4AHRITGB3ITGAVPLAU
SCHEMBL29717704 0.79 RAPGEF4 (0.35) RAPGEF4AHRITGB3ITGAVPLAU
SCHEMBL3786224 0.77 RAPGEF4 (0.47) RAPGEF4AHRNOTUMADORA2AADORA1
SCHEMBL321756 0.77 AHR (0.52) RAPGEF4AHRNOTUMADORA2AADORA1
SCHEMBL17433203 0.77 TSHR (0.50) ITGB3ITGAVPLAUALDH1A1CYP3A4
SCHEMBL17403485 0.76 AHR (0.35) RAPGEF4AHRITGB3ITGAVPLAU
Nitrogen SCHEMBL9592328 0.72 AHR (0.48) RAPGEF4AHRNOTUMADORA2AADORA1
SCHEMBL10153360 0.72 AHR (0.35) RAPGEF4AHRITGB3ITGAVNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382218-B2 N-heteroaryl substituted aniline derivatives as HCV-antivirals HOFFMANN-LA ROCHE INC. (US) 2016-07-05 US disclosed
US-20160000763-A1 N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS HOFFMANN-LA ROCHE INC. 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000763-A1 N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS HAVCR2, UGT1A1, UGT1A3 RAPGEF4 3433/4885AHR 286/4885ITGB3 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.